BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China’s Innovent Doses First Patient in Phase 3 Trial of HER2-Targeted ADC for Ovarian Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

March 25, 2025 | Report

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Dizal to Present New Findings on Golidocitinib-PD-1 Combo and Sunvozertinib-Anlotinib Therapy at ELCC 2025

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...

March 21, 2025 | News

Zhejiang Doer Biologics Completes Phase 2 Enrollment for First-in-Class Tri-Agonist DR10624 in Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

March 11, 2025 | News

Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety

Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...

March 10, 2025 | News

Japan’s AMR Response 2013–2025: Key Lessons and Global Implications

The World Health Organization (WHO) Regional Office for the Western Pacific (WPRO) has released Japan’s AMR Response 2013–2025, providing a com...

February 26, 2025 | News

Kangpu Biopharma Secures China IND Approval for KPG-818 in Relapsed/Refractory Multiple Myeloma

Kangpu Biopharmaceuticals, Ltd. ("Kangpu") announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National...

February 26, 2025 | News

Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

February 25, 2025 | News

Sanyou Bio Advances Drug Discovery with 10-Trillion Molecule Platform

Sanyou Biopharmaceuticals Co., Ltd. (Sanyou Bio), a world-leading biotechnology company specializing in innovative biologic drug research and development, ...

February 24, 2025 | News

CanSinoBIO Showcases Vaccine Innovation and Global Health Commitment at 2025 World Government Summit

CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai...

February 18, 2025 | News

TAHO Pharmaceuticals’ Apixaban Oral Dissolving Film Shows Positive Results in Pivotal Study

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The s...

February 18, 2025 | News

RemeGen Presents Promising Phase II Trial Results for Disitamab Vedotin and Toripalimab in Muscle-Invasive Bladder Cancer at ASCO GU 2025

RemeGen Co., Ltd. (RemeGen) has announced new efficacy and safety data from the Phase II clinical trial (NCT05297552, Study ID: RC48-C017) evaluating Disit...

February 17, 2025 | News

Taiwan's Caliway Biopharmaceuticals Reports Groundbreaking Results for CBL-514 in U.S. and Canada Phase 2b Study

Caliway Biopharmaceuticals unveiled the impressive results of its second Phase 2b clinical study (CBL-0205) for CBL-514, the world’s first in...

February 11, 2025 | News

Allurion Technologies to Initiate Clinical Study Combining Allurion Program with GLP-1 Therapy to Transform Obesity Care

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its ...

January 24, 2025 | News

Stay Connected